Non-small cell lung cancer, MET-mutated

From - A Hematology Oncology Wiki
Jump to: navigation, search
Page editor Section editor
Amit Kulkarni.jpg
Amit Kulkarni, MBBS
University of Minnesota
Minneapolis, MN

Social-twitter-icon.png AmitKulkarniMD
Travis Osterman, DO, MS, FAMIA
Vanderbilt University
Nashville, TN

Social-twitter-icon.png TravisOsterman

Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.

1 regimens on this page
1 variants on this page

Metastatic disease

Capmatinib monotherapy

back to top


FDA-recommended dose
Study Years of enrollment Evidence
Wolf et al. 2020 (GEOMETRY mono-1) NR Phase II (RT)

Biomarker Eligibility Criteria

  • Biomarker: MET exon 14 skipping

Targeted therapy

Continued indefinitely


  1. GEOMETRY mono-1: Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. link to original article contains protocol PubMed NCT02414139